LBF20307PG38 - Revision history

Editor at 00:00, 17 January 2014

2014-01-17T00:00:00Z

@@ Line 19: / Line 19: @@
 |Symbol=PGJ2
 |Biological Activity=The anti-tumor and anti-viral activities of prostaglandin J2 are attributed to  Delta 12-prostaglandin J2 which is a degradation product of prostagladnin J2 and is characteristic of its alkylidene cyclopentenone structure [[Reference:Fukushima_M:,Prostaglandins Leukot. Essent. Fatty Acids,1992,47,1|{{RelationTable/GetFirstAuthor|Reference:Fukushima_M:,Prostaglandins Leukot. Essent. Fatty Acids,1992,47,1}}]].
 }}
 {{Lipid/Footer}}

Editor at 09:02, 21 October 2010

2010-10-21T09:02:35Z

← Older revision		Revision as of 18:02, 21 October 2010
Line 6:		Line 6:
	\|LipidBank=XPR1901		\|LipidBank=XPR1901
	\|LipidMaps=LMFA03010019		\|LipidMaps=LMFA03010019
	\|SysName=7- [2R- (3S-~~Hydroxy~~-1~~-trans~~-octenyl) -3-oxo-4-cyclopenten-1R-yl] -5~~-cis~~-heptenoic acid		\|SysName=7- [2R- (3S-hydroxy-trans-1-octenyl) -3-oxo-4-cyclopenten-1R-yl] -cis-5-heptenoic acid
	\|Common Name=&&Prostaglandin J_2&&7- [2R- (3S-Hydroxy-1-(E)-octenyl) -3-oxo-4-cyclopenten-1R-yl] -5-(Z)-heptenoic acid&&		\|Common Name=&&Prostaglandin J_2&&7- [2R- (3S-Hydroxy-1-(E)-octenyl) -3-oxo-4-cyclopenten-1R-yl] -5-(Z)-heptenoic acid&&
	\|Solubility=ACETONITRILE<!--以下1048-->[[Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093\|		\|Solubility=ACETONITRILE<!--以下1048-->[[Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093\|

Editor at 06:14, 28 May 2010

2010-05-28T06:14:32Z

← Older revision		Revision as of 15:14, 28 May 2010
Line 6:		Line 6:
	\|LipidBank=XPR1901		\|LipidBank=XPR1901
	\|LipidMaps=LMFA03010019		\|LipidMaps=LMFA03010019
	\|SysName=7- [ 2 (R) - (3 (S) -Hydroxy-1 (E) -octenyl) -3-oxo-4-cyclopenten-~~1 (R)~~ -yl ] -5 (Z) -heptenoic acid		\|SysName=7- [2R- (3S-Hydroxy-1-trans-octenyl) -3-oxo-4-cyclopenten-1R-yl] -5-cis-heptenoic acid
	~~\|Common Name=&&Prostaglandin J_2~~&&		\|Common Name=&&Prostaglandin J_2&&7- [2R- (3S-Hydroxy-1-(E)-octenyl) -3-oxo-4-cyclopenten-1R-yl] -5-(Z)-heptenoic acid&&
	\|Solubility=ACETONITRILE<!--以下1048-->[[Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093\|		\|Solubility=ACETONITRILE<!--以下1048-->[[Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093\|
	{{RelationTable/GetFirstAuthor\|Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093}}]], CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		{{RelationTable/GetFirstAuthor\|Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093}}]], CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]

Editor at 06:05, 12 May 2010

2010-05-12T06:05:01Z

← Older revision		Revision as of 15:05, 12 May 2010
Line 8:		Line 8:
	\|SysName=7- [ 2 (R) - (3 (S) -Hydroxy-1 (E) -octenyl) -3-oxo-4-cyclopenten-1 (R) -yl ] -5 (Z) -heptenoic acid		\|SysName=7- [ 2 (R) - (3 (S) -Hydroxy-1 (E) -octenyl) -3-oxo-4-cyclopenten-1 (R) -yl ] -5 (Z) -heptenoic acid
	\|Common Name=&&Prostaglandin J_2&&		\|Common Name=&&Prostaglandin J_2&&
	\|Solubility=ACETONITRILE<!--以下1048-->[[~~Reference:~~Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093\|		\|Solubility=ACETONITRILE<!--以下1048-->[[Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093\|
	{{RelationTable/GetFirstAuthor\|Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093}}]], CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		{{RelationTable/GetFirstAuthor\|Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093}}]], CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]

Editor at 06:04, 12 May 2010

2010-05-12T06:04:18Z

← Older revision		Revision as of 15:04, 12 May 2010
Line 9:		Line 9:
	\|Common Name=&&Prostaglandin J_2&&		\|Common Name=&&Prostaglandin J_2&&
	\|Solubility=ACETONITRILE<!--以下1048-->[[Reference:Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093\|		\|Solubility=ACETONITRILE<!--以下1048-->[[Reference:Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093\|
	{{RelationTable/GetFirstAuthor\|Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093}}]]		{{RelationTable/GetFirstAuthor\|Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093}}]], CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	, CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|UV Spectra= lambda ^{MeOH}_{max} = 305( epsilon 1200), 216( epsilon 9900)nm [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|UV Spectra= lambda ^{MeOH}_{max} = 305( epsilon 1200), 216( epsilon 9900)nm [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]

Editor at 06:03, 12 May 2010

2010-05-12T06:03:55Z

← Older revision		Revision as of 15:03, 12 May 2010
Line 8:		Line 8:
	\|SysName=7- [ 2 (R) - (3 (S) -Hydroxy-1 (E) -octenyl) -3-oxo-4-cyclopenten-1 (R) -yl ] -5 (Z) -heptenoic acid		\|SysName=7- [ 2 (R) - (3 (S) -Hydroxy-1 (E) -octenyl) -3-oxo-4-cyclopenten-1 (R) -yl ] -5 (Z) -heptenoic acid
	\|Common Name=&&Prostaglandin J_2&&		\|Common Name=&&Prostaglandin J_2&&
	\|Solubility=ACETONITRILE<!--~~1048~~-->		\|Solubility=ACETONITRILE<!--以下1048-->[[Reference:Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093\|
	[[Reference:Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093\|
	{{RelationTable/GetFirstAuthor\|Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093}}]]		{{RelationTable/GetFirstAuthor\|Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093}}]]
	, CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		, CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]

Editor at 06:03, 12 May 2010

2010-05-12T06:03:27Z

← Older revision		Revision as of 15:03, 12 May 2010
Line 8:		Line 8:
	\|SysName=7- [ 2 (R) - (3 (S) -Hydroxy-1 (E) -octenyl) -3-oxo-4-cyclopenten-1 (R) -yl ] -5 (Z) -heptenoic acid		\|SysName=7- [ 2 (R) - (3 (S) -Hydroxy-1 (E) -octenyl) -3-oxo-4-cyclopenten-1 (R) -yl ] -5 (Z) -heptenoic acid
	\|Common Name=&&Prostaglandin J_2&&		\|Common Name=&&Prostaglandin J_2&&
	\|Solubility=ACETONITRILE<!--1048-->, CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|Solubility=ACETONITRILE<!--1048-->
			[[Reference:Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093\|
			{{RelationTable/GetFirstAuthor\|Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093}}]]
			, CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|UV Spectra= lambda ^{MeOH}_{max} = 305( epsilon 1200), 216( epsilon 9900)nm [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|UV Spectra= lambda ^{MeOH}_{max} = 305( epsilon 1200), 216( epsilon 9900)nm [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]

Editor at 05:35, 23 April 2010

2010-04-23T05:35:46Z

← Older revision		Revision as of 14:35, 23 April 2010
Line 7:		Line 7:
	\|LipidMaps=LMFA03010019		\|LipidMaps=LMFA03010019
	\|SysName=7- [ 2 (R) - (3 (S) -Hydroxy-1 (E) -octenyl) -3-oxo-4-cyclopenten-1 (R) -yl ] -5 (Z) -heptenoic acid		\|SysName=7- [ 2 (R) - (3 (S) -Hydroxy-1 (E) -octenyl) -3-oxo-4-cyclopenten-1 (R) -yl ] -5 (Z) -heptenoic acid
	\|Common Name=&&~~PROSTAGLANDIN~~ J_2&&		\|Common Name=&&Prostaglandin J_2&&
	\|Solubility=ACETONITRILE<!--1048-->, CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|Solubility=ACETONITRILE<!--1048-->, CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]

Dbmanager at 21:00, 14 April 2010

2010-04-14T21:00:00Z

← Older revision		Revision as of 06:00, 15 April 2010
Line 7:		Line 7:
	\|LipidMaps=LMFA03010019		\|LipidMaps=LMFA03010019
	\|SysName=7- [ 2 (R) - (3 (S) -Hydroxy-1 (E) -octenyl) -3-oxo-4-cyclopenten-1 (R) -yl ] -5 (Z) -heptenoic acid		\|SysName=7- [ 2 (R) - (3 (S) -Hydroxy-1 (E) -octenyl) -3-oxo-4-cyclopenten-1 (R) -yl ] -5 (Z) -heptenoic acid
	\|Common Name=&&PROSTAGLANDIN J_2~~&&7- [ 2 (R) - (3 (S) -Hydroxy-1 (E) -octenyl) -3-oxo-4-cyclopenten-1 (R) -yl ] -5 (Z) -heptenoic acid~~&&		\|Common Name=&&PROSTAGLANDIN J_2&&
	\|Solubility=ACETONITRILE<!--1048-->, CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|Solubility=ACETONITRILE<!--1048-->, CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]

Dbmanager at 10:00, 25 February 2010

2010-02-25T10:00:10Z

← Older revision		Revision as of 19:00, 25 February 2010
Line 10:		Line 10:
	\|Solubility=ACETONITRILE<!--1048-->, CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|Solubility=ACETONITRILE<!--1048-->, CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|UV Spectra= lambda ^~~M_m _a _x~~ = 305( epsilon 1200), 216( epsilon 9900)nm [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|UV Spectra= lambda ^{MeOH}_{max} = 305( epsilon 1200), 216( epsilon 9900)nm [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|IR Spectra= nu 3400, 3200, 2660, 1710, 1085, 970 cm^- ^1 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|IR Spectra= nu 3400, 3200, 2660, 1710, 1085, 970 cm^{-1} [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|NMR Spectra=^1 H-NMR(CDCl_3 ) : delta 7.75-7.55(m, 1H, 9-CH), 6.30-6.10(m, 1H, 10-CH), 5.90(brs, 2H, OH), 5.75-5.35(m, 4H), 4.30-3.95(m, 1H, 15-CH) [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|NMR Spectra=^1 H-NMR(CDCl_3 ) : delta 7.75-7.55(m, 1H, 9-CH), 6.30-6.10(m, 1H, 10-CH), 5.90(brs, 2H, OH), 5.75-5.35(m, 4H), 4.30-3.95(m, 1H, 15-CH) [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|Source=		\|Source=

← Older revision		Revision as of 15:04, 12 May 2010
Line 9:		Line 9:
	\|Common Name=&&Prostaglandin J_2&&		\|Common Name=&&Prostaglandin J_2&&
	\|Solubility=ACETONITRILE<!--以下1048-->[[Reference:Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093\|		\|Solubility=ACETONITRILE<!--以下1048-->[[Reference:Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093\|
	{{RelationTable/GetFirstAuthor\|Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093}}]]		{{RelationTable/GetFirstAuthor\|Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093}}]], CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	, CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|UV Spectra= lambda ^{MeOH}_{max} = 305( epsilon 1200), 216( epsilon 9900)nm [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|UV Spectra= lambda ^{MeOH}_{max} = 305( epsilon 1200), 216( epsilon 9900)nm [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]

← Older revision		Revision as of 19:00, 25 February 2010
Line 10:		Line 10:
	\|Solubility=ACETONITRILE<!--1048-->, CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|Solubility=ACETONITRILE<!--1048-->, CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|Mass Spectra=TMS ETHER ; M^+ 478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|UV Spectra= lambda ^~~M_m _a _x~~ = 305( epsilon 1200), 216( epsilon 9900)nm [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|UV Spectra= lambda ^{MeOH}_{max} = 305( epsilon 1200), 216( epsilon 9900)nm [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|IR Spectra= nu 3400, 3200, 2660, 1710, 1085, 970 cm^- ^1 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|IR Spectra= nu 3400, 3200, 2660, 1710, 1085, 970 cm^{-1} [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|NMR Spectra=^1 H-NMR(CDCl_3 ) : delta 7.75-7.55(m, 1H, 9-CH), 6.30-6.10(m, 1H, 10-CH), 5.90(brs, 2H, OH), 5.75-5.35(m, 4H), 4.30-3.95(m, 1H, 15-CH) [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]		\|NMR Spectra=^1 H-NMR(CDCl_3 ) : delta 7.75-7.55(m, 1H, 9-CH), 6.30-6.10(m, 1H, 10-CH), 5.90(brs, 2H, OH), 5.75-5.35(m, 4H), 4.30-3.95(m, 1H, 15-CH) [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790\|{{RelationTable/GetFirstAuthor\|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
	\|Source=		\|Source=